Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer.

Jing NieHuina WuQian WuLihui LiuKe TangShuo WangJiyong Wu

Published in: Cost effectiveness and resource allocation : C/E (2024)

Pembrolizumab was less cost-effective for patients with platinum-pretreated, recurrent or metastatic NPC compared with chemotherapy in China.

Keyphrases